Calibrate, MD-Led Platform

Calibrate is a New York-based metabolic health company founded in 2020 with a specific thesis: that GLP-1 medications work best when paired with structured behavioral change, not prescribed in isolation. The company's flagship offering, the Metabolic Reset, is a twelve-month program combining FDA-approved GLP-1 prescriptions (semaglutide, tirzepatide, liraglutide, dulaglutide) with biweekly one-on-one coaching and a self-paced curriculum covering food, sleep, exercise, and emotional health. The clinical model is built around board-certified clinicians who manage GLP-1 prescribing and dose titration throughout the year, supported by a coaching team that provides ongoing accountability and behavioral guidance. Unlike platforms that hand patients a prescription and a pharmacist phone number, Calibrate keeps the clinical and coaching relationship active for the full twelve months. Internal outcome data covering more than 16,000 members shows an average of 16.2% body weight loss at twelve months — a result the company attributes to the behavioral component amplifying medication efficacy. Calibrate accepts commercial health insurance for GLP-1 medications and handles prior authorization on behalf of members. The program fee itself ($199/month) is not covered by insurance but is HSA/FSA eligible. Members with commercial plans often achieve per-month medication costs of $25 or less once their deductible is met. The program is designed for adults who take obesity seriously as a chronic condition and are willing to invest in a full-year treatment approach. Calibrate is not positioned as a budget option — the combination of program fees and potential medication costs makes it one of the more expensive telehealth weight loss platforms. However, for patients whose primary care physician has not offered structured obesity medicine support, Calibrate provides the clinical depth and continuity that is often absent from both traditional primary care and low-cost telehealth alternatives. Calibrate published peer-reviewed outcome data in 2023 and has positioned itself as an evidence-based alternative to both direct-to-consumer compounding services and traditional in-office obesity medicine clinics. The company operates across the majority of US states and targets commercially insured adults as its primary patient population. The company's flagship offering, the Metabolic Reset, is a twelve-month program combining FDA-approved GLP-1 prescriptions (semaglutide, tirzepatide, liraglutide, dulaglutide) with biweekly one-on-one coaching and a self-paced curriculum covering food, sleep, exercise, and emotional health. The clinical model is built around board-certified clinicians who manage GLP-1 prescribing and dose titration throughout the year, supported by a coaching team that provides ongoing accountability and behavioral guidance. Unlike platforms that hand patients a prescription and a pharmacist phone number, Calibrate keeps the clinical and coaching relationship active for the full twelve months. Internal outcome data covering more than 16,000 members shows an average of 16.2% body weight loss at twelve months — a result the company attributes to the behavioral component amplifying medication efficacy. Calibrate accepts commercial health insurance for GLP-1 medications and handles prior authorization on behalf of members. The program fee itself ($199/month) is not covered by insurance but is HSA/FSA eligible. Members with commercial plans often achieve per-month medication costs of $25 or less once their deductible is met. The program is designed for adults who take obesity seriously as a chronic condition and are willing to invest in a full-year treatment approach. Calibrate is not positioned as a budget option — the combination of program fees and potential medication costs makes it one of the more expensive telehealth weight loss platforms. However, for patients whose primary care physician has not offered structured obesity medicine support, Calibrate provides the clinical depth and continuity that is often absent from both traditional primary care and low-cost telehealth alternatives. Calibrate published peer-reviewed outcome data in 2023 and has positioned itself as an evidence-based alternative to both direct-to-consumer compounding services and traditional in-office obesity medicine clinics. The company operates across the majority of US states and targets commercially insured adults as its primary patient population.